The Growth Stock Report Genx**Genx**Genx**Genx**Genx**Genx**Genx** Record Earnings Announcement Coming Monday August 16, 2004 Biotech Sizzle with Sales and Earnings!! Genex Pharmaceutical, Inc.(OTCBB: GENX) (Treating Bone Related Injuries in China) Revenues from 2/10/03 (Inception) to 12/31/03: $1,221,903 Net Income from 2/10/03 (Inception) to 12/31/03: $450,985 Revenues 3 months 3/31/04; $436,208 Net Income 3 months 3/31/04: $66,691 The Company paid $0 for interest and income tax during the period ended March 1,2003 and the years ended Dec.31,2003. (Source: 8K Filed 6/29/04) Genx**Genx**Genx**Genx**Genx**Genx**Genx** Look how these Chinese Stocks have done and what they would've made your portfolio look like if you knew about them: (OTCBB:CAAS):Closed September 2, 2003 at $4.00. Closed December 31, 2003: $16.65, Up 316% (OTCBB:CWTD):Closed January 30, 2004 at $1.50. Closed February 17th at $7.90, Up 426% Ordinary Investors Like You are Turbocharging Their Portfolios With these High Octane Stocks. When Some of Them Start to Move, They Really Take Off. The interesting thing about companies that do business in China is that the market and 0pportunity is much, much bigger than in the USA. And that can mean sweet, juicy pr0fits for savvy investors who take advantage of them. This bad boy (GENX) is out of Stealth Mode and is already top line revenue producing! Do you see where we're going with this? Biotech Sizzle with Sales and Earnings!! Genx**Genx**Genx**Genx**Genx**Genx**Genx** About Genex Pharmaceutical, Inc. Genex Pharmaceutical, Inc. is a biomedical technology company with distinctive proprietary technology for an orthopedic device that treats bone-related injuries. Headquartered in Tianjin, China, the Company manufactures and distributes Reconstituted Bone Xenograft (RBX), to 400 hospitals in 22 provinces throughout mainland China. RBX is approved by the State Food and Drug Administration (SFDA) in China (the Chinese government agency that regulates drugs and medical devices). RBX offers a modern alternative to traditional methods of treating orthopedic injuries. (Source: News Release 7/27/04) Genx**Genx**Genx**Genx**Genx**Genx**Genx** Recent Press Release: July 27th (NEW PRODUCT BEING TESTED) Tuesday July 27, 5:42 pm ET Chinese FDA Approves Clinical Trials of Genex's New Dental Product NEW YORK--(BUSINESS WIRE)--July 27, 2004--Genex Pharmaceutical, Inc. (stock symbol: GENX; a Delaware corporation, is a profitable biomedical technology company with a unique product for treating various bone-related injuries called Reconstituted Bone Xenograft (RBX), which is a medical device approved by the SFDA (Chinese State Food and Drug Administration). RBX is suitable for compound or complex bone fractures, compression fractures and intractable fractures, bone defects, vertebral column or joint rehabilitation and for bone absence after tumor removal such as a bone cyst. The SFDA has approved clinical trials of the company's new product for dental applications, micro-particle RBX. The clinical trials will focus on orthodontic and periodontal procedures. Micro-particle RBX provides a minimally invasive technique that will improve dental surgery procedures and potentially accelerate recovery from surgeries. "Approval for clinical trials of micro-particle RBX is a significant step in the development and expansion of our product pipeline. We are extending our success of treating orthopedic surgical patients with RBX to the vast number of dental patients seeking minimally invasive technologies in orthodontic treatment," commented Mr. Fuzhi Song, Chairman and CEO of Genex. According to a National Dental Survey conducted by the PRC Ministry of Health, from 1995 to 1998, 570 million Chinese people suffer from advanced tooth decay, 80% of Chinese people over the age of 7 suffer from permanent tooth decay, 4% over 60 need gum treatment and 2% of the nation's over 40 population require dental grafting. Genx**Genx**Genx**Genx**Genx**Genx**Genx** Good Luck and Succesful Trading. Go GENEX!! DIS-CLAIMER: Information within this email contains "F0RWARD looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "F0RWARD looking statements."F0RWARD looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. F0RWARD looking statements in this action may be identified through the use of words such as "projects", "foresee", "expects", "will," "anticipates," "estimates," "believes," "understands" or that by statements indicating certain actions "may," "could," or "might" occur. As with many micro-cap stocks, today's company has additional risk factors worth noting. Those factors include: the company advancing cash to related parties and a shareholder on an unsecured basis: one vendor, a related party through a majority stockholder, supplies ninety-seven percent of the company's raw materials: reliance on two customers for over fifty percent of their business and numerous related party transactions and the need to raise capital. The Growth Stock Report does not represent that the information contained in this message states all material facts or does not omit a material fact necessary to make the statements therein not misleading.All information provided within this em-ail pertaining to investing, stocks, securities must be understood as information provided and not investment advice. The Growth Stock Report advises all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this em-ail. None of the material within this report shall be construed as any kind of investment advice or solicitation.Many of these companies are on the verge of bankruptcy. You can lose all your money by investing in this stock. The publisher of The Growth Stock Report is not a registered investment ADVIS0R. Subscribers should not view information herein as legal, tax, accounting or investment advice. Any reference to past performance(s) of companies are specially selected to be referenced based on the favorable performance of these companies. You would need perfect timing to acheive the results in the examples given. There can be no assurance of that happening. Remember, as always, past performance is ne-ver indicative of future results and a thorough due diligence effort, including a review of a company's filings, should be completed prior to investing.The Growth Stock Report has no relationship with CAAS and CWTD. (Source for Price Information:Yahoo Finance Historical). In compliance with the Securities Act of 1933, Section17(b),The Growth Stock Report discloses the receipt of twelve thousand dollars from a third party, not an officer, director or affiliate shareholder for the circulation of this report. Be aware of an inherent conflict of interest resulting from such compensation due to the fact that this is a paid adver-tisement. All factual information in this report was gathered from public sources, including but not limited to Company Websites, SEC Filings and Company Press Releases. The Growth Stock Report believes this information to be reliable but can make no guar-antee as to its accuracy or completeness. Use of the material within this em-ail constitutes your acceptance of these terms.